Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis
Status:
Unknown status
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Yeast vaginitis is a very common ailment affecting premenopausal women in Nigeria. This
condition is more prevalent in the age group between 21-30 years. More than 75% of
premenopausal women and university students are diagnosed with yeast infections annually. In
most of these women, recurrent rate of vaginal candidiasis with empiric therapy, stands
between 70 and 80%. In addition, resistance to anti-fungal agents is increasing at an
alarming speed, particularly with species other than Candida albicans such as C tropicalis
and C glabrata. The healthy vaginal environment is composed mainly of lactobacilli and when
these organisms are suppressed overgrowth of a large number of pathogens occur including
yeasts. In this pilot study,we hypothesize that oral administration of two well documented
strains of lactobacilli (L.rhamnosis GR-1 and L.reuteri RC-14 ) given to women with recurrent
yeast vaginitis, following standard therapy with fluconazole will result in a significant
reduction in recurrence rate of the disease.